Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.37 |
| ▸ | MGAM | O43451 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | SI | P14410 | 1/20 | 0.37 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.37 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.35 |
| ▸ | RECQL | P46063 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.30 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8206001 | 0.79 | TSHR (0.42) | TSHRHSD17B10MGAMGAASI | |
| SCHEMBL678682 | 0.75 | — | — | |
| SCHEMBL10954155 | 0.74 | TSHR (0.42) | TSHRHSD17B10MGAMGAASI | |
| SCHEMBL1523144 | 0.70 | TSHR (0.48) | TSHRHSD17B10MGAMGAASI | |
| SCHEMBL11140368 | 0.70 | TSHR (0.42) | TSHRHSD17B10MGAMGAASI | |
| SCHEMBL18334512 | 0.69 | TSHR (0.46) | TSHRHSD17B10MGAMGAASI | |
| SCHEMBL30876013 | 0.69 | — | — | |
| SCHEMBL10482256 | 0.69 | TSHR (0.46) | TSHRHSD17B10MGAMGAASI | |
| SCHEMBL5692424 | 0.69 | TSHR (0.46) | TSHRHSD17B10MGAMGAASI | |
| SCHEMBL11804545 | 0.68 | TSHR (0.36) | TSHRHSD17B10MGAMGAASI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025128106-A1 | PHARMACEUTICAL INTERMEDIATES AND METHODS FOR PREPARING THE SAME IN THE SYNTHESIS OF MUSCIMOL AND CONGENERS AND DERIVATIVES THEREOF | BOULANGER WILLIAM ALLEN (US) | 2025-06-19 | — | — | WO | disclosed |
| US-11998531-B1 | Pharmaceutical intermediates and methods for preparing the same in the synthesis of muscimol and congeners and derivatives thereof | BOULANGER, WILLIAM ALLEN | 2024-06-04 | — | — | US | disclosed |
| EP-0346852-B1 | Process for producing 4-chloro-3-alkoxybut-2E-ene acid alkyl esters | LONZA AG (CH) | 1994-02-23 | — | — | EP | disclosed |
| EP-0216324-B1 | 4-ALKOXY-3-PYRROLIN-2-ONE-1-YL-ACETIC ACID ALKYL AND BENZYL ESTERS AND THEIR PREPARATION | LONZA AG (CH) | 1990-11-22 | — | — | EP | disclosed |
| US-4966989-A | KETALIZATION AND ESTERIFICATION OF 4-CHLOROACETOACETYL CHLORIDE WITH AN ALCOHOL AND A DIALKYL SULFITE | LONZA LTD. (CH) | 1990-10-30 | — | — | US | disclosed |
| US-4788294-A | Process for the production of 4-alkoxy-3-pyrrolin-2-ones | LONZA LTD. (CH) | 1988-11-29 | — | — | US | disclosed |
| EP-0216324-A2 | 4-Alkoxy-3-pyrrolin-2-one-1-yl-acetic acid alkyl and benzyl esters and their preparation | LONZA AG (CH) | 1987-04-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11998531-B1 | Pharmaceutical intermediates and methods for preparing the same in the synthesis of muscimol and congeners and derivatives thereof | OPRM1, MSMO1, COMT | TSHR 1018/4885HSD17B10 2121/4885MGAM 294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.